Simrat Randhawa, Executive Vice President and Head of Research and Development at Dianthus Therapeutics, Inc. (NASDAQ:DNTH), completed a set of equity transactions on March 12, 2026. On that date, Randhawa sold 33,830 shares of the companys common stock at $81.48 per share, resulting in proceeds of $2,756,468.
Also on March 12, Randhawa exercised stock options to acquire 33,830 shares of Dianthus common stock. The option exercises were executed in a series of transactions with exercise prices spanning $8.44 to $22.07, and the aggregate exercise cost totaled $614,165.
An InvestingPro note in the reporting cites that the company holds more cash than debt on its balance sheet, and indicates 16 additional exclusive tips are available to subscribers.
Randhawa's transactions come amid a significant capital raise by Dianthus. The company completed an underwritten public offering that generated approximately $719 million in gross proceeds. That offering included the sale of 8,470,989 shares of common stock at $81 per share, reflecting proceeds that incorporated shares issued upon full exercise of the underwriters option to purchase additional shares. In addition to the common shares, Dianthus issued pre-funded warrants to purchase up to 402,468 shares at $80.999 per warrant; those warrants are exercisable immediately.
The recent $719 million transaction replaced an earlier announced $625 million stock offering priced at the same $81 per share. Separately, the company had disclosed a $400 million stock offering intended to support clinical and preclinical development as well as commercial readiness activities.
Following interim data from the Phase 3 CAPTIVATE study in chronic inflammatory demyelinating polyneuropathy, several brokerages adjusted their coverage. Raymond James upgraded Dianthus to a Strong Buy and set a price target of $123, citing positive interim results from that study. Clear Street raised its price target to $130 and maintained a Buy rating after Dianthus decided to proceed to Part B of the trial.
Note: The figures and events reported above reflect the transactions and company actions disclosed as part of the March 12, 2026 filings and subsequent company announcements.